Evidence snapshot
- Regulatory update
- Mounjaro prescribing information revised August 2026
- Trial
- SURPASS-CVOT (NCT04255433)
- Randomized
- 13,299 participants
- Comparator
- Dulaglutide 1.5 mg once weekly
- Primary result
- HR 0.92 (95.3% CI 0.83–1.01)
- Conclusion
- Non-inferior; superiority not established
Key takeaways
- FDA-approved Mounjaro® now has a product-specific indication to reduce the risk of major adverse cardiovascular events in certain high-risk adults with type 2 diabetes.
- SURPASS-CVOT established that tirzepatide was non-inferior to dulaglutide for the primary cardiovascular outcome; it did not establish superiority.
- The peer-reviewed trial reported a primary event in 12.2% of the tirzepatide group and 13.1% of the dulaglutide group, with a hazard ratio of 0.92.
- The indication applies to FDA-approved Mounjaro® and should not be transferred automatically to compounded products, research materials, or other products described as tirzepatide.
What changed?
Mounjaro® is an FDA-approved prescription medicine containing tirzepatide. Its prescribing information was revised in August 2026 to add an indication for reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for those events.
The newly listed major cardiovascular events are:
- Cardiovascular death
- Non-fatal myocardial infarction, commonly called a heart attack
- Non-fatal stroke
What was already approved?
Mounjaro was already indicated, along with diet and exercise, to improve blood glucose control in adults and pediatric patients 10 years of age and older with type 2 diabetes.
The August 2026 update adds cardiovascular risk reduction as a separate, product-specific indication for certain high-risk adults. That is meaningful because cardiovascular disease is a major complication associated with type 2 diabetes.
The study behind the decision
The cardiovascular evidence comes from SURPASS-CVOT, a large randomized, double-blind clinical trial comparing tirzepatide with dulaglutide in people with type 2 diabetes and established atherosclerotic cardiovascular disease.
A total of 13,299 participants underwent randomization. After 134 participants who did not meet the inclusion criteria were excluded, the modified intention-to-treat analysis included 6,586 participants assigned to tirzepatide and 6,579 assigned to dulaglutide.
The primary endpoint was the time to the first occurrence of cardiovascular death, myocardial infarction, or stroke—the three-part composite commonly called MACE-3.
What did SURPASS-CVOT find?
A primary cardiovascular event occurred in 801 participants assigned to tirzepatide, or 12.2%, and 862 participants assigned to dulaglutide, or 13.1%. The hazard ratio was 0.92, with a 95.3% confidence interval from 0.83 to 1.01.
The trial met its primary statistical objective by demonstrating that tirzepatide was non-inferior to dulaglutide for the combined cardiovascular outcome.
The study did not establish statistical superiority of tirzepatide over dulaglutide for that primary endpoint. It would therefore be inaccurate to describe SURPASS-CVOT as proving that Mounjaro was superior to dulaglutide for preventing cardiovascular events.
Why this matters for Type 2 diabetes
Type 2 diabetes management involves more than monitoring blood glucose. People with type 2 diabetes can also face increased cardiovascular risk, which is why cardiovascular outcomes have become an important part of evaluating modern diabetes medications.
The new Mounjaro indication means that cardiovascular risk reduction is now included in the FDA-approved prescribing information for adults with type 2 diabetes who are at high risk for these events.
Mounjaro and tirzepatide are not interchangeable terms
Tirzepatide is the drug substance. Mounjaro® is the specific FDA-approved prescription product containing tirzepatide and marketed by Eli Lilly and Company.
An FDA approval or clinical outcome involving Mounjaro should not automatically be attributed to unrelated products marketed simply as tirzepatide. Compounded drugs and research materials are not automatically FDA-approved because they are described using the same drug name.
The bottom line
The August 2026 label expansion represents an important development in the treatment of type 2 diabetes. FDA-approved Mounjaro® now carries an indication for reducing the risk of cardiovascular death, non-fatal heart attack, and non-fatal stroke in adults with type 2 diabetes who are at high risk for these events.
The evidence supports that product-specific indication while also requiring an important limit: SURPASS-CVOT showed non-inferiority to dulaglutide, not statistical superiority for the primary cardiovascular endpoint.
Evidence over hype.
Evidence, in proportion
What the evidence shows—and what it does not.
What it shows
- The August 2026 Mounjaro prescribing information includes a cardiovascular risk-reduction indication for adults with type 2 diabetes who are at high risk for major cardiovascular events.
- In SURPASS-CVOT, tirzepatide met the prespecified statistical objective for non-inferiority to dulaglutide on the MACE-3 composite endpoint.
- The peer-reviewed trial reported event rates of 12.2% with tirzepatide and 13.1% with dulaglutide in its modified intention-to-treat population.
What it does not show
- That tirzepatide was statistically superior to dulaglutide for the trial’s primary cardiovascular endpoint.
- That the Mounjaro indication applies to every compounded product, research material, or other preparation described as tirzepatide.
- That a population-level trial result determines the right prescription or expected outcome for an individual patient.
The PONY takeaway
FDA-approved Mounjaro® now has a product-specific indication to reduce the risk of major adverse cardiovascular events in certain high-risk adults with type 2 diabetes. The remaining context determines how far that fact can travel.
Frequently asked
Common questions
What is Mounjaro’s new cardiovascular indication?+
Mounjaro is now indicated to reduce the risk of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke in adults with type 2 diabetes who are at high risk for those events.
Did tirzepatide outperform dulaglutide in SURPASS-CVOT?+
No. Tirzepatide met the trial’s non-inferiority objective, meaning it was not unacceptably worse than dulaglutide under the prespecified margin. Statistical superiority was not established for the primary MACE-3 endpoint.
Does the indication apply to every tirzepatide product?+
No. The indication belongs to FDA-approved Mounjaro and its approved prescribing information. It does not automatically apply to compounded preparations, research materials, or unrelated products described as tirzepatide.
Primary references
Sources
- Mounjaro® — U.S. Prescribing Information
FDA-approved prescribing information revised August 2026, including the new cardiovascular indication and the label’s SURPASS-CVOT summary.
- New England Journal of Medicine — Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
Primary peer-reviewed SURPASS-CVOT publication reporting the trial design, analysis population, event rates, hazard ratio, and non-inferiority and superiority tests.
- ClinicalTrials.gov — SURPASS-CVOT (NCT04255433)
Official trial registration for the randomized comparison of tirzepatide and dulaglutide on major cardiovascular events.
- FDA — Concerns with unapproved GLP-1 drugs used for weight loss
FDA guidance explaining that unapproved semaglutide and tirzepatide products do not undergo the agency’s premarket review for safety, effectiveness, and quality.
Editorial disclosure
This article discusses the FDA-approved prescription product Mounjaro® and the published clinical evidence supporting its approved labeling. References to FDA approval apply to the approved product and its approved indications, not to other products or materials described as tirzepatide. Mounjaro® is a registered trademark of Eli Lilly and Company. Peppy Pony is not affiliated with or endorsed by Eli Lilly and Company.
This article is provided for general educational and informational purposes only. It is not medical advice, a treatment recommendation, or an offer to sell or promote any prescription or investigational drug. Treatment decisions involving prescription medicines should be made with a qualified healthcare professional.